LBRX — LB Pharmaceuticals Inc Dilution Risk Tracker

LB Pharmaceuticals Inc (LBRX) has a DilutionScore of 48/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

The most significant dilution vector for LBRX is its shelf registration capacity of $100.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely.

DilutionWatch tracks over 25 SEC filing types for LBRX in real-time, scanning EDGAR every 60 seconds. A recent S-3 or registration statement filing appears in LBRX's filing history — this warrants monitoring for subsequent prospectus supplements (Form 424B), which indicate active capital raising. The DilutionWatch screener shows real-time score changes for LBRX alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.